Ahead of its fourth quarter results, Canaccord Genuity analyst Neil Maruoka says investors should take a long look at Aurora Cannabis (TSXV:ACB). On Monday, Aurora will report its fourth quarter and fiscal 2017 results. Maruoka thinks the company will report EPS of $0.02 and EBITDA of $3.5-million on revenue of $7.8-million. The analyst says there […]
Scientific Games offer for NYX Gaming is fair, M Partners says
Scientific Games proposed acquisition of NYX Gaming (TSX:NYX) is a fair one, says M Partners analyst Zach Greenwald. On Wednesday, NYX Gaming announced it had agreed to be acquired for approximately $775-million by Las Vegas-based Scientific Games Corp. “Scientific Games’ acquisition of NYX will provide immediate and compelling cash value for our shareholders, expand the […]
Canopy Growth Corp. is a first-mover on the international market, GMP says
A partnership that will bring Canada’s Canopy Growth Corp. (TSX:WEED) into the Danish market is a positive development, GMP Securities analyst Martin Landry says. This morning, Canopy announced it had reached a partnership with Danish Cannabis ApS to form a new firm called Spectrum Denmark ApS. Canopy said despite impending legalization in that country, the […]
DHX Media is undervalued, says Canaccord Genuity
Ahead of the company’s fourth quarter results, Canaccord Genuity analyst Aravinda Galappatthige remains bullish on DHX Media (TSX:DHX). On September 28, before the market open, DHX will report its fourth quarter and fiscal 2017 results. Galappatthige thinks the company will post Adjusted EBITDA of $37.35-million on revenue of $98.62-million, a topline that would be up […]
Promis Neurosciences could have a groundbreaking Alzheimer’s treatment, Mackie Research says
Promis Neurosciences (TSX:PMN) is sitting on an Alzheimer’s drug candidate that could prove to be best-in-class, says Mackie Research Capital analyst André Uddin. In a research report to clients today, Uddin inititated coverage of Promis Neurosciences with a “Speculative Buy” rating and one-year price target of $0.50, implying a return of 104 per cent at […]
ProMetic Life Sciences has 197% upside, says Canaccord Genuity
New data from ProMetic Life Sciences’ (TSX:PLI) ongoing phase 2 open-label clinical trial is giving Canaccord Genuity analyst Neil Maruoka more confidence in his bullish target on the stock. This morning, ProMetic reported what it described as positive clinical data from its continuing phase two trial in which patients suffering from Alstrom syndrome were administered […]
Why is AI (Finally) Happening Now?
Editors Note: This is Part Two of a special feature is brought to you courtesy Industrial Alliance Securities and analyst Blair Abernethy. It will run in multiple parts over the next two weeks in Cantech Letter. For part one and to read disclaimers click here. Why is AI (Finally) Happening Now? AI research efforts have […]
Canaccord Genuity raises price target on Oncolytics Biotech to $2.50
The end of Oncolytics Biotech (TSX:ONC, Nasdaq:ONCY) phase two meetings with the FDA have derisked the story, says Canaccord Genuity analyst Neil Maruoka. This morning, Oncolytics Biotech announced it had completed the successful end of its phase two meeting with the FDA for Reolysin in combination with paclitaxel, for the treatment of hormone receptor positive, […]
Organigram Holdings is still undervalued, says GMP
A supply agreement with the province of New Brunwick is a strong vote of confidence in Organigram (TSXV:OGI), says GMP Securities analyst Martin Landry. On Friday, Organigram announced it had entered into a memorandum of understanding with the province of New Brunswick that will see the former supply a minimum of five-million grams of recreational […]
CGI likely to remain active on the M&A front, Canaccord Genuity says
A $300-million stock buyback isn’t likely to dampen the enthusiasm of CGI Group (TSX:GIB.A, NYSE:GIB) for acquisitions, says Canaccord Genuity analyst Robert Young. On Thursday, CGI Group announced it intends to repurchase 4.85-million of its shares held by Caisse de depot, which would be left with about 46.2-million shares, or 16 per cent of CGI. […]
- 1
- 2
- 3
- …
- 212
- Next Page »